When the Obama administration announced its plan to test new ways of paying for prescription drugs under Medicare Part B, a slew of criticism from industry stakeholders quickly followed--though some say they see potential in the new models.
Citing a new report that found prescription drug spending reached $457 billion in 2015, the federal government announced it will test new Medicare Part B payment models to try to tackle those spiraling costs.
Cancer drug waste costs the Medicare program and private insurers billions of dollars each year, according to a new report from The BMJ.
Health insurer Cigna has teamed up with Swiss drugmaker Novartis AG to set the price for a new heart medication based on performance, Reuters reports.
It may now be easier for hospitals to improve outcomes at lower costs by claiming both "urban" and "rural" status, thanks to a ruling by the 2 nd U.S. Circuit Court of Appeals in New York.
Twenty major companies are teaming up to keep the amount they spend on employee healthcare as low as possible.
Despite presidential candidates promising to reduce the out-of-pocket costs of prescription drugs, a new article from STAT makes the case that the amount of power the government actually has to drive down drug prices on a large scale may not be significant.
Drug prices are increasing due to the fact that many health insurers cover few prescriptions, including those that are old and should be priced very low, Scott Gottleib of the American Enterprise Institute writes in a post for Forbes.
Drug makers and insurance companies may finally be leaning toward some form of mutual understanding and compromise about rising prescription prices, according to STAT News.
Even if a Democrat wins the White House, the candidate would have little chance of implementing his or her plans unless the party controls both the House and Senate, argues an article in the National Journal.